TY - JOUR
T1 - Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy
AU - Kabashima, Akira
AU - Kitagawa, Dai
AU - Nakamura, Toshihiko
AU - Kondo, Naoko
AU - Teramoto, Seiichi
AU - Saito, Genkichi
AU - Funahashi, Tomoru
AU - Adachi, Eisuke
AU - Ikeda, Yoichi
PY - 2014/11/1
Y1 - 2014/11/1
N2 - A 63-year-old woman underwent a low anterior resection for rectal cancer in 2002.A n anastomotic recurrence was diagnosed in July 2011.S he rejected the possibility of colostomy as radical surgery.Chemotherapy consisting of capecitabine+ oxaliplatin (XELOX) or folinic acid, fluorouracil, and oxaliplatin (FOLFOX6) + bevacizumab were not possible because of high costs. In view of the lower costs and the potential for ambulation, S-1 monotherapy was started. After 3 months, a reduction in the recurrent lesion was observed.After 19 months, the recurrent lesion revealed a scar, which was judged by biopsy to be Group 1.We had achieved a pathological complete response (CR).The standard treatment for recurrent colon cancer is surgical resection or multidrug chemotherapy. However, in view of a patient's quality of life (QOL), S-1 monotherapy may be considered as a potential therapy.
AB - A 63-year-old woman underwent a low anterior resection for rectal cancer in 2002.A n anastomotic recurrence was diagnosed in July 2011.S he rejected the possibility of colostomy as radical surgery.Chemotherapy consisting of capecitabine+ oxaliplatin (XELOX) or folinic acid, fluorouracil, and oxaliplatin (FOLFOX6) + bevacizumab were not possible because of high costs. In view of the lower costs and the potential for ambulation, S-1 monotherapy was started. After 3 months, a reduction in the recurrent lesion was observed.After 19 months, the recurrent lesion revealed a scar, which was judged by biopsy to be Group 1.We had achieved a pathological complete response (CR).The standard treatment for recurrent colon cancer is surgical resection or multidrug chemotherapy. However, in view of a patient's quality of life (QOL), S-1 monotherapy may be considered as a potential therapy.
UR - http://www.scopus.com/inward/record.url?scp=84928416815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928416815&partnerID=8YFLogxK
M3 - Article
C2 - 25731306
SN - 0385-0684
VL - 41
SP - 1716
EP - 1718
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 12
ER -
